These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31007877)

  • 21. Systematic reviews of ten pharmaceutical pricing policies - a research protocol.
    Tordrup D; van den Ham HA; Glanville J; Mantel-Teeuwisse AK
    J Pharm Policy Pract; 2020; 13():22. PubMed ID: 32695425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform.
    Chen Y; Hu S; Dong P; Kornfeld Å; Jaros P; Yan J; Ma F; Toumi M
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical Pricing: The Use of External Reference Pricing.
    Ruggeri K; Nolte E
    Rand Health Q; 2013; 3(2):6. PubMed ID: 28083293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea.
    Hasan SS; Kow CS; Dawoud D; Mohamed O; Baines D; Babar ZU
    Value Health Reg Issues; 2019 May; 18():18-23. PubMed ID: 30414506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of external reference pricing on pharmaceutical costs and market dynamics.
    Voehler D; Koethe BC; Synnott PG; Ollendorf DA
    Health Policy Open; 2023 Dec; 4():100093. PubMed ID: 37383884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing pharmaceutical pricing - a scoping review of academic literature in health science.
    Borges Dos Santos MA; Dos Santos Dias LL; Santos Pinto CDB; da Silva RM; Osorio-de-Castro CGS
    J Pharm Policy Pract; 2019; 12():24. PubMed ID: 31391943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review.
    Wettstein DJ; Boes S
    Appl Health Econ Health Policy; 2019 Apr; 17(2):143-162. PubMed ID: 30367350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence.
    Wettstein DJ; Boes S
    Health Policy; 2022 Feb; 126(2):112-121. PubMed ID: 35000803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis.
    Dahmani H; Fradi I; Achour L; Toumi M;
    J Mark Access Health Policy; 2023; 11(1):2244304. PubMed ID: 37614557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.
    Nguyen TA; Knight R; Roughead EE; Brooks G; Mant A
    Health Policy Plan; 2015 Mar; 30(2):267-80. PubMed ID: 24425694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
    Håkonsen H; Horn AM; Toverud EL
    Health Policy; 2009 May; 90(2-3):277-85. PubMed ID: 19042052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
    Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 37. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
    Kaló Z; Muszbek N; Bodrogi J; Bidló J
    Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Policy in the Czech Republic.
    Skoupá J
    Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan.
    Shiroiwa T
    Int J Technol Assess Health Care; 2020 Jun; 36(3):270-276. PubMed ID: 32419677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.